Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that the sports and wellness group, USN will be preparing more products with Phytofare as ingredient. These products will be launched in the markets of New Zealand and Australia. The products will have green tea catechin-based Phytofare®. USN has accepted the numerous benefits of phyto-availability in order to meet the customer’s need of best quality products.
Phytofare® ingredient has the ability to supply increased number of the active ingredients to the blood where ingredients stay functional much longer than generic products. This feature results in noticeable health effects.
On Wednesday’s trading session, the share price of Plandai plunged more than 6% to close the trading session at $0.140. The drop came at a share volume of 35,151 compared to average share volume of 72,064.
Flex Pharma Inc (NASDAQ:FLKS) Announces Change In Board
Flex Pharma Inc (NASDAQ:FLKS) a biotechnology entity developing effective treatments for exercise-resulting nocturnal leg and muscle cramps, and spasms problems from neuromuscular conditions, announced that Mr. Robert J. Perez, the ex-Chief Executive of Cubist Pharmaceuticals Inc (NASDAQ:CBST) will now be a part of company’s Board.
Flex Pharma reported that Mr. Perez has been with Cubist Pharmaceuticals since 2003. He has served as Senior VP, Sales and Marketing and contributed in the launch of Cubicin®. He was the COO and Executive VP for Cubist from 2007 to year 2012. Prior to Cubist, he was VP of CNS business division of Biogen Inc (NASDAQ:BIIB)’s from 2001 to 2003, where he headed commercial operations of neurology business segment. Mr. Perez is an active member on the Board of firms, Cidara Therapeutics Inc (NASDAQ:CDTX) as well as AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).
After the release of PR, the stock of Flex Pharma posted strong gains to close around $0.241. It extended the gains in following session and jumped more than 11% to close the day at $0.270.
